BTIG analyst Mark Massaro raised the firm’s price target on Exact Sciences (EXAS) to $85 from $75 and keeps a Buy rating on the shares. The company has executed well following its commercial reorganization in its recent prior quarters, and clocked 22% Y/Y growth in its core screening business in Q3 on the back of making further progress with Cologuard rescreens and health plan care gap orders, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $80 from $67 at Stifel
- Exact Sciences: Strong Growth Potential and Strategic Initiatives Justify Buy Rating
- Exact Sciences price target raised to $77 from $65 at Barclays
- Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target
- Exact Sciences Reports Record Q3 Revenue and Raises Guidance